Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
20 May, 2019 14:18 IST
Lupin launches generic Silodosin capsules in United States
Source: IRIS | 05 Dec, 2018, 09.54AM
Comments  |  Post Comment

Pharma major Lupin announced the launch of Silodosin Capsules 4mg and 8mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Silodosin Capsules 4mg and 8mg; is the generic equivalent of Allergan's Rapaflo. An alpha-1 adrenergic receptor antagonist, it is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Rapaflo had annual sales of USD 198.5 million in the US (IQVIA MAT September 2018).

Shares of the company declined Rs 10.35, or 1.17%, to trade at Rs 877.70. The total volume of shares traded was 26,434 at the BSE (9.47 a.m., Wednesday).

Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer